Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 3
2005 2
2007 1
2008 5
2010 4
2011 6
2012 7
2013 10
2014 3
2015 9
2016 13
2017 6
2018 18
2019 9
2020 9
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 22890289

95 results

Results by year

Filters applied: . Clear all
Page 1
Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H. Ikeda T, et al. Hematol Oncol. 2019 Dec;37(5):586-594. doi: 10.1002/hon.2688. Epub 2019 Nov 23. Hematol Oncol. 2019. PMID: 31674032
Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
Parmar H, Al Saleh AS, Visram A, Warsame R, Kourelis T, Gonsalves W, Dingli D, Muchtar E, Hayman S, Kapoor P, Buadi F, Dispenzieri A, Lacy M, Gertz M, Kumar S. Parmar H, et al. Transplant Cell Ther. 2021 Apr;27(4):309.e1-309.e5. doi: 10.1016/j.jtct.2020.11.022. Epub 2020 Dec 17. Transplant Cell Ther. 2021. PMID: 33836869 Free article.
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Kuruvilla J, et al. Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. doi: 10.1016/j.bbmt.2007.04.006. Epub 2007 May 29. Biol Blood Marrow Transplant. 2007. PMID: 17640596 Free article. Clinical Trial.
Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G, Falcone AP, Minervini MM, De Cillis GP, De Waure C, Sisti LG, Giambra V, Valente D, Chiello V, Scalzulli PR, Carella AM, Cascavilla N. Rossi G, et al. Cytometry B Clin Cytom. 2019 May;96(3):195-200. doi: 10.1002/cyto.b.21755. Epub 2018 Dec 13. Cytometry B Clin Cytom. 2019. PMID: 30549231 Free article.
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Björkstrand B, et al. J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. J Clin Oncol. 2011. PMID: 21730266
95 results